Fortress Biotech Announces an Exclusive License Agreement for FB-607 for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D)

Stock Information for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026
Journey Medical Corporation to Participate in September 2026 Investor Conferences
Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duties by Certain Officers and Directors of Fortress Biotech, Inc. (NASDAQ: FBIO)
Journey Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.